Disruptive Nutrition Announces Clinical Research Study for Nutritional Intervention in Angelman Syndrome
December 1, 2017 – Chicago, IL – Disruptive Nutrition announced today it is sponsoring a clinical research study at Vanderbilt University Medical Center to evaluate the safety and tolerability of a novel nutritional formulation for children with Angelman syndrome. The nutritional formulation can be used with standard, ketogenic, and low glycemic index diets.
Disruptive Nutrition Founder Mike McCandless, Disruptive Nutrition Chief Science Officer Donna Herber, Ph.D., and Assistant Professor of Pediatrics at Vanderbilt University Medical Center Jessica Duis, MD, made the announcement at the FAST (Foundation for Angelman Syndrome Therapeutics) Summit in Chicago.
“One of the main reasons I founded Disruptive Nutrition was to advance disease research and develop supplements that can potentially benefit patients,” said Disruptive Nutrition Founder Mike McCandless. “I’ve always been interested in the connection between diet and health and I’m excited about partnering with Vanderbilt to hopefully make meaningful progress toward a cure for Angelman syndrome.”
Angelman syndrome is a rare genetic disorder caused by disruption in the UBE3A gene. It is characterized by developmental delays, including speech impairment and movement disorders. Eighty percent of patients have seizures, and a large proportion of the population also have feeding and sleep problems. The majority of children ages 4-11 with Angelman syndrome receive medication for seizures in addition to physical, occupational, and speech therapies. Some children with treatment-resistant seizures may also have special dietary interventions, such as the ketogenic diet. A low-carb/high-fat diet is a natural way to transition the brain to alternative sources of energy, which may decrease the excitability of the brain, thus minimizing seizure activity. By participating in this clinical study, children with Angelman syndrome may help medical researchers learn more about this genetic disorder and possible future treatment options.
The FAST Summit and Gala is an annual 2-day event that includes a science summit, educational workshops, and a celebrity fundraiser. It draws more than 1,000 people from around the world. Last year’s event raised more than $1.3 million. Actor Colin Farrell will be this year’s guest speaker at the gala. His son was diagnosed with AS at the age of two.
FAST is led by Paula Evans, who has a daughter with Angelman syndrome. Through FAST, she is working with more than two dozen scientists from multiple universities and pharmaceutical companies to find a cure. Part of their effort includes human clinical testing of potential treatments for Angelman syndrome.
About Disruptive Nutrition, LLC
By advancing novel approaches that target whole body metabolism, our mission at Disruptive Nutrition is to provide high quality nutrition products backed by scientific evidence to support health and wellness. Disruptive Nutrition develops products formulated to not only promote health, but also boost the body’s own ability to combat disease in rare genetic disorders. We strive to work with researchers at the cutting edge of truly disruptive innovation, and then design products that meet the unique needs and qualities of the patient.
Disruptive Nutrition is a subsidiary of Disruptive Enterprises, LLC, which is committed to making innovative new foods, beverages, dietary supplements, and medical foods accessible to help more people realize the benefits of a ketogenic (low-carb/high-fat) diet. Other subsidiary operating companies include KetoLogic, LLC and Love You Foods, LLC. Together, the companies conduct research, develop intellectual property, and formulate, market, and distribute consumer packaged goods designed to help people live healthier happier lives.
About Foundation for Angelman Syndrome Therapeutics (FAST)
FAST is an all-volunteer organization of families and professionals dedicated to finding a cure for Angelman syndrome and related disorders through the funding of an aggressive research agenda, education, and advocacy. The Foundation is committed to assisting individuals living with Angelman syndrome to realize their full potential and quality of life. Its goal is to bring practical treatment into current medical practice as quickly as possible.